NASDAQ:KNSA - Kiniksa Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $18.15 +1.06 (+6.20 %) (As of 11/15/2018 04:00 PM ET)Previous Close$17.09Today's Range$16.31 - $19.7052-Week Range$13.04 - $32.88Volume62,200 shsAverage Volume108,751 shsMarket Capitalization$905.47 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda. Receive KNSA News and Ratings via Email Sign-up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KNSA Previous Symbol CUSIPN/A Webwww.kiniksa.com Phone781-439-9100 Debt Debt-to-Equity RatioN/A Current Ratio12.19 Quick Ratio12.19 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$6.45 per share Price / Book2.81 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees47 Outstanding Shares49,450,000Market Cap$905.47 million OptionableNot Optionable Kiniksa Pharmaceuticals (NASDAQ:KNSA) Frequently Asked Questions What is Kiniksa Pharmaceuticals' stock symbol? Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA." How were Kiniksa Pharmaceuticals' earnings last quarter? Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) announced its earnings results on Thursday, November, 1st. The company reported ($0.51) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.54) by $0.03. View Kiniksa Pharmaceuticals' Earnings History. When is Kiniksa Pharmaceuticals' next earnings date? Kiniksa Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 7th 2019. View Earnings Estimates for Kiniksa Pharmaceuticals. What price target have analysts set for KNSA? 4 equities research analysts have issued 12-month target prices for Kiniksa Pharmaceuticals' shares. Their predictions range from $29.00 to $44.00. On average, they expect Kiniksa Pharmaceuticals' stock price to reach $34.6667 in the next year. This suggests a possible upside of 91.0% from the stock's current price. View Analyst Price Targets for Kiniksa Pharmaceuticals. What is the consensus analysts' recommendation for Kiniksa Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kiniksa Pharmaceuticals. Has Kiniksa Pharmaceuticals been receiving favorable news coverage? News coverage about KNSA stock has trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Kiniksa Pharmaceuticals earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. Who are some of Kiniksa Pharmaceuticals' key competitors? Some companies that are related to Kiniksa Pharmaceuticals include FibroGen (FGEN), Emergent Biosolutions (EBS), Ligand Pharmaceuticals (LGND), Array Biopharma (ARRY), Evotec (EVTCY), Intercept Pharmaceuticals (ICPT), Endo International (ENDP), Madrigal Pharmaceuticals (MDGL), Mallinckrodt (MNK), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Allakos (ALLK) and Supernus Pharmaceuticals (SUPN). Who are Kiniksa Pharmaceuticals' key executives? Kiniksa Pharmaceuticals' management team includes the folowing people: Mr. Stephen Mahoney, Pres and Chief Operating OfficerMr. Thomas W. Beetham, Chief Legal OfficerDr. John F. Paolini, Chief Medical OfficerMr. Rasmus Holm-Jørgensen, Sr. VP, Chief Strategy and Portfolio Officer. When did Kiniksa Pharmaceuticals IPO? (KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. When does Kiniksa Pharmaceuticals' lock-up period expire? Kiniksa Pharmaceuticals' lock-up period expires on Tuesday, November 20th. Kiniksa Pharmaceuticals had issued 8,477,777 shares in its IPO on May 24th. The total size of the offering was $152,599,986 based on an initial share price of $18.00. After the end of Kiniksa Pharmaceuticals' lock-up period, major shareholders and company insiders will be able to sell their shares of the company. Who are Kiniksa Pharmaceuticals' major shareholders? Kiniksa Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (1.57%), BlackRock Inc. (0.91%), VHCP Management III LLC (0.66%), Vivo Capital LLC (0.54%), Victory Capital Management Inc. (0.27%) and Citadel Advisors LLC (0.11%). Company insiders that own Kiniksa Pharmaceuticals stock include Bros Advisors Lp Baker, Cormorant Asset Management, Lp and James E Flynn. View Institutional Ownership Trends for Kiniksa Pharmaceuticals. Which institutional investors are selling Kiniksa Pharmaceuticals stock? KNSA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Perceptive Advisors LLC, Citadel Advisors LLC and Victory Capital Management Inc.. View Insider Buying and Selling for Kiniksa Pharmaceuticals. Which institutional investors are buying Kiniksa Pharmaceuticals stock? KNSA stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., VHCP Management III LLC, Vivo Capital LLC, Bank of New York Mellon Corp, Alps Advisors Inc. and American International Group Inc.. Company insiders that have bought Kiniksa Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Cormorant Asset Management, Lp and James E Flynn. View Insider Buying and Selling for Kiniksa Pharmaceuticals. How do I buy shares of Kiniksa Pharmaceuticals? Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Kiniksa Pharmaceuticals' stock price today? One share of KNSA stock can currently be purchased for approximately $18.15. How big of a company is Kiniksa Pharmaceuticals? Kiniksa Pharmaceuticals has a market capitalization of $905.47 million. Kiniksa Pharmaceuticals employs 47 workers across the globe. What is Kiniksa Pharmaceuticals' official website? The official website for Kiniksa Pharmaceuticals is http://www.kiniksa.com. How can I contact Kiniksa Pharmaceuticals? Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 781-439-9100 or via email at [email protected] MarketBeat Community Rating for Kiniksa Pharmaceuticals (NASDAQ KNSA)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 35 (Vote Outperform)Underperform Votes: 32 (Vote Underperform)Total Votes: 67MarketBeat's community ratings are surveys of what our community members think about Kiniksa Pharmaceuticals and other stocks. Vote "Outperform" if you believe KNSA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KNSA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/15/2018 by MarketBeat.com StaffFeatured Article: What is a balanced fund?